M.SzumlanskiC
evidence mixed) Example discussed online: semaglutide + AOD-9604 Mechanistic logic: GLP-1-based meds drive appetite reduction, improved glycemic regulation, and downstream weight loss
Lowe, Senescence of activated stellate cells limits liver fibrosis
Increased serum and brain concentrations of lactate, pyruvate, lactate/pyruvate ratio, alanine, and creatine kinase, at 31%, 14%, 28%, 8%, 47%, 35%, 46%, and 7%, respectively, and low carnitine were described in 90% of children with ASD in the review of Rossignol and Frye [38]
Critical realities to understand: Weight loss is not linear - Plateaus are normal and don't mean the medication stopped working Lifestyle matters - GLP-1 medications reduce appetite, but they don't make weight loss effortless
Target Dose (Monotherapy/Combination): The common target dose used in major clinical trials is 2.4 mg per week